Search

everythinglearnresearchcommunity

for

Search:↓

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Frequent blood transfusions in beta thalassemia can lead to thyroid problems.

Birt–Hogg–Dubé Syndrome requires genetic testing for accurate diagnosis due to its similarities with tuberous sclerosis.

TPA is about 50 times more effective at promoting tumors than MZ.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.

Telogen effluvium is a common hair loss condition requiring careful diagnosis and treatment.

The report expanded knowledge of MBTPS1-related disorders by identifying new symptoms.

Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

High-dose biotin can cause false thyroid test results; stop taking biotin two days before testing to avoid errors.

People with TED often have low B12 levels and might benefit from B12 supplements.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

The combination treatment showed a higher response rate but no significant survival benefits.

Thymosin β4 helps improve skin healing and reduce scarring.

CTP-543 is generally safe for treating alopecia areata.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

TECAR therapy helps with pain relief, reduces inflammation, relaxes muscles, heals tissues, and is safe and effective for many conditions.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

Promising cancer treatments were found, but the manufacturer closed.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

A child with trichothiodystrophy also had autoimmune thyroiditis and anemia, which is a new finding.

Truncated LTBP-1 disrupts TGF-beta signaling, affecting hair growth.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Betacellulin helps blood vessel growth in wounds but delays hair growth.

The Swedish neonatal screening program effectively detects PKU, galactosaemia, and biotinidase deficiency with low false positives.

Trichothiodystrophy is a rare genetic disorder causing hair issues and sometimes linked to DNA repair defects.

Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.